KannaLife

From Wikipedia, the free encyclopedia
Jump to: navigation, search
KannaLife Sciences Inc.
Private
Industry Pharmaceutical
Founded 2010
Founders Dean Petkanas, Thoma Kikis
Headquarters Doylestown, Pennsylvania And Huntington, New York
Total assets Exclusive License of patent US 6630507 
Website http://kannalife.com
KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent US 6630507  “Cannabinoids as Antioxidants and Neuroprotectants."

KannaLife Sciences Inc. is a bio-pharmaceutical and phyto-medical company based in Huntington, NY and Doylestown, Pennsylvania founded by Dean Petkanas and Thoma Kikis.[1] KannaLife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. It is a portfolio company of Medical Marijuana, Inc..[2]

In 2011, the company was granted an Exclusive License[3] by National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of patent US 6630507 , “Cannabinoids as Antioxidants and Neuroprotectants."[4]

KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County[5] in Doylestown, PA, for a target drug candidate to treat Hepatic encephalopathy and CTE,[6] an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.

References[edit]